HER2 Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
CONCLUSIONS: These findings identify HER2 as a biomarker for IRX4204 treatment response and demonstrate a novel use of RXR agonists to synergize with current anti-HER2 therapies. Furthermore, our results suggest that RXR agonists can be useful for the treatment of anti-HER2 resistant and metastatic HER2-positive breast cancer.PMID:38578278 | DOI:10.1158/1078-0432.CCR-23-3839 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Cassandra L Moyer Amanda Lanier Jing Qian Darian Coleman Jamal Hill Vidyasagar Vuligonda Martin E Sanders Abhijit Mazumdar Powel H Brown Source Type: research

Telangiectasias induced by combination tucatinib and ado-trastuzumab emtansine in a patient with metastatic breast cancer
CONCLUSIONS: We postulate that telangiectasias may be a previously unreported dermatologic side effect of combination treatment with tucatinib and T-DM1. Electrocautery is a safe and effective procedure to reduce the appearance of telangiectasias and improve patient satisfaction during chemotherapy.PMID:38578876 | DOI:10.3233/BD-230053 (Source: Breast Disease)
Source: Breast Disease - April 5, 2024 Category: Cancer & Oncology Authors: Gabriella F Rodriguez Anuj Shah Andrea D Maderal Source Type: research

PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report
CONCLUSION: PRaG 3.0 might be a novel strategy for HER2-positive metastatic PDAC patients who failed from previous first-line approach and even PD-1 immunotherapy but needs more data in prospective trials.PMID:38577174 | PMC:PMC10989490 | DOI:10.3748/wjg.v30.i9.1237 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - April 5, 2024 Category: Gastroenterology Authors: Yue-Hong Kong Mei-Ling Xu Jun-Jun Zhang Guang-Qiang Chen Zhi-Hui Hong Hong Zhang Xiao-Xiao Dai Yi-Fu Ma Xiang-Rong Zhao Chen-Yang Zhang Rong-Zheng Chen Peng-Fei Xing Li-Yuan Zhang Source Type: research

PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report
CONCLUSION: PRaG 3.0 might be a novel strategy for HER2-positive metastatic PDAC patients who failed from previous first-line approach and even PD-1 immunotherapy but needs more data in prospective trials.PMID:38577174 | PMC:PMC10989490 | DOI:10.3748/wjg.v30.i9.1237 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - April 5, 2024 Category: Gastroenterology Authors: Yue-Hong Kong Mei-Ling Xu Jun-Jun Zhang Guang-Qiang Chen Zhi-Hui Hong Hong Zhang Xiao-Xiao Dai Yi-Fu Ma Xiang-Rong Zhao Chen-Yang Zhang Rong-Zheng Chen Peng-Fei Xing Li-Yuan Zhang Source Type: research

Case report: Primary vulvar adenocarcinoma of mammary gland type-its genetic characteristics by focused next-generation sequencing
We present the case of a 59-year-old female with an ulcerated mass on the right side of the external genitalia, diagnosed as MLVA. Comprehensive immunohistochemistry (IHC) and gene sequencing studies were performed to characterize the tumor. IHC analysis revealed triple expression of hormonal receptors (estrogen receptor, progesterone receptor, and HER2), supporting the mammary gland origin of the tumor. Gene sequencing identified unique genetic mutations associated with the expression of hormonal markers. One fusion gene (ERBB2-NAGLU) has not been reported in any tumors, and other mutations with unique mutation types have...
Source: Pathology Oncology Research - April 4, 2024 Category: Pathology Authors: Lina Hu James Tiesinga Source Type: research

Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Conclusion: In the PHERGain trial, an increased SUVmax cutoff (≥77%) after 2 cycles of exclusive HP (with or without endocrine therapy) achieves a pCR in the range of the control arm with chemotherapy plus HP (59.5% vs. 57.7%, respectively), further identifying a subgroup of patients with HER2-addicted tumors. However, the original cutoff (≥40%) maximizes the number of patients who could avoid chemotherapy.PMID:38575192 | DOI:10.2967/jnumed.123.266384 (Source: Cancer Control)
Source: Cancer Control - April 4, 2024 Category: Cancer & Oncology Authors: Geraldine Gebhart Marleen Keyaerts Thomas Guiot Patrick Flamen Manuel Ruiz-Borrego Agostina Stradella Bego ña Bermejo Santiago Escriva-de-Romani Lourdes Calvo Mart ínez Nuria Ribelles Mar ía Fernandez-Abad Cinta Albacar Marco Colleoni Laia Garrigos Man Source Type: research

Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience
CONCLUSION: There are limited studies published on the efficacy and post-treatment toxicities of metastatic breast cancer OM and OP SABR with adequate length of follow-up. This study confirmed that SABR was a safe, non-invasive treatment option for patients with extracranial OM and OP diseases originated from primary breast cancer in terms of the acceptable post-treatment toxicities.PMID:38575431 | DOI:10.1016/j.clon.2024.03.012 (Source: Cancer Control)
Source: Cancer Control - April 4, 2024 Category: Cancer & Oncology Authors: S Armstrong A Makris K Belessiotis-Richards M Abdul-Latif P Ostler N Shah D Miles Y M Tsang Source Type: research